Achaogen is a South San Francisco-based biopharmaceutical company with expertise in the discovery, development and commercialisation of new antibacterial drugs, particularly products that treat multi-drug resistant (MDR) gram-negative
The company's interdisciplinary teams are made up of seasoned professionals that enable Achaogen to design and conduct large, global clinical trials.
Achaogen’s therapeutic antibody efforts are focused on developing monoclonal antibodies (mAb) that are attractive as antibacterial agents. This expertise has allowed Achaogen to identify and build a portfolio of product candidates for the treatment of infections due to MDR gram-negative pathogens.
Download to find out more.